|

SC-101 in Subjects With Advanced NECTIN4-Amplified Cancers

RECRUITINGPhase 2Sponsored by Tianjin ConjuStar Biologics Co., Ltd.
Actively Recruiting
PhasePhase 2
SponsorTianjin ConjuStar Biologics Co., Ltd.
Started2025-08-26
Est. completion2027-07-30
Eligibility
Age18 Years – 75 Years
Healthy vol.Accepted

Summary

This study is an open-label, multicenter Phase IIa trial to evaluate the efficacy and safety of SC-101 monotherapy in patients with locally advanced or metastatic malignant tumors who are positive for NECTIN4 gene amplification.

Eligibility

Age: 18 Years – 75 YearsHealthy volunteers accepted
Inclusion Criteria:

Age between 18 and 75 years (inclusive), regardless of gender.

ECOG performance status of 0-1.

Expected survival of more than 3 months, as assessed by the investigator.

Fertile participants must agree to use contraception.

Able to understand the trial requirements and willing and able to comply with the trial and follow-up procedures.

Adequate bone marrow and organ function.

NECTIN-4 gene amplification positive.

Exclusion Criteria:

Unstable central nervous system tumors.

Adverse reactions from previous anticancer treatments have not recovered to a CTCAE 5.0 grade ≤1.

A history of severe cardiovascular or cerebrovascular disease.

Conditions4

Breast CancerCancerHR+ Breast CancerTNBC - Triple-Negative Breast Cancer

Interventions1

Related trials

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.